Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi

Key Points

• Amundi cut its Ironwood Pharmaceuticals stake by 37.1% in the first quarter, selling 238,593 shares and retaining 404,237 shares valued at approximately $1.42 million.
• Ironwood reported quarterly earnings of $0.31 per share and revenue of $113.04 million, slightly below analyst expectations of $0.32 EPS and $114.84 million in revenue.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $6.23 versus the stock’s reported price of $4.32; insiders also recently sold shares.

Amundi trimmed its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 37.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 404,237 shares of the biotechnology company's stock after selling 238,593 shares during the period. Amundi owned approximately 0.25% of Ironwood Pharmaceuticals worth $1,419,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. purchased a new position in Ironwood Pharmaceuticals in the fourth quarter valued at $3,897,000. GSA Capital Partners LLP grew its stake in Ironwood Pharmaceuticals by 84.7% during the 4th quarter. GSA Capital Partners LLP now owns 571,613 shares of the biotechnology company's stock worth $1,926,000 after purchasing an additional 262,084 shares in the last quarter. Globeflex Capital L P purchased a new stake in Ironwood Pharmaceuticals during the 1st quarter worth about $912,000. Inspire Investing LLC purchased a new stake in Ironwood Pharmaceuticals during the 1st quarter worth about $1,790,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at about $613,000.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock opened at $4.32 on Friday. The firm has a market cap of $704.41 million, a P/E ratio of 5.61 and a beta of 0.20. Ironwood Pharmaceuticals, Inc. has a 1-year low of $0.81 and a 1-year high of $5.78. The firm has a fifty day moving average of $3.90 and a two-hundred day moving average of $3.97.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%.The business had revenue of $113.04 million for the quarter, compared to analyst estimates of $114.84 million. On average, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.04 EPS for the current year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In related news, insider Ronald Silver sold 127,890 shares of the business's stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total transaction of $578,062.80. Following the sale, the insider owned 313,680 shares of the company's stock, valued at $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Julie Mchugh sold 21,571 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total transaction of $80,459.83. Following the sale, the director directly owned 250,749 shares of the company's stock, valued at approximately $935,293.77. This represents a 7.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 9.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Wall Street Zen downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of Ironwood Pharmaceuticals in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $6.23.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company's flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source